Contact
searchSearch
HMP Global
Login
Manisha Palta, MD, Duke University Cancer Center
Videos
An Argument for Radiation in the Neoadjuvant Setting for Pancreatic Cancer
03/23/2023
At the 2023 ACRO Radiation Oncology Summit, Manisha Palta, MD, discussed the role of radiation therapy in the neoadjuvant setting for patients with pancreatic cancer.
At the 2023 ACRO Radiation Oncology Summit, Manisha Palta, MD, discussed the role of radiation therapy in the neoadjuvant setting for patients with pancreatic cancer.
At the 2023 ACRO Radiation...
03/23/2023
Oncology
Gerard Morton, MD, Odette Cancer Center at Sunnybrook Research Institute
Videos
Methods of Radiation Dose Intensification for High-Risk Prostate Cancer
03/21/2023
At the 2023 ACRO Radiation Oncology Summit, Gerard Morton, MD, discusses the different methods of radiation dose intensification for patients with high-risk prostate cancer.
At the 2023 ACRO Radiation Oncology Summit, Gerard Morton, MD, discusses the different methods of radiation dose intensification for patients with high-risk prostate cancer.
At the 2023 ACRO Radiation...
03/21/2023
Oncology
Mylin Torres, MD, Winship Cancer Institute
Videos
Five-Fraction Radiation Regimens for Early-Stage Breast Cancer
03/20/2023
At the 2023 ACRO Radiation Oncology Summit, Mylin Torres, MD, gave a presentation exploring the option of 5-fraction radiation regimens for patients with early-stage breast cancer.
At the 2023 ACRO Radiation Oncology Summit, Mylin Torres, MD, gave a presentation exploring the option of 5-fraction radiation regimens for patients with early-stage breast cancer.
At the 2023 ACRO Radiation...
03/20/2023
Oncology
Maria Werner-Wasik, MD, Sidney Kimmel Cancer Center
Videos
Chemoimmunotherapy and the Changing Landscape of Preoperative Treatment for Stage III Non-Small Cell Lung Cancer
03/20/2023
At the 2023 ACRO Radiation Oncology Summit, Maria Werner-Wasik, MD, discussed preoperative treatment options for stage III non-small cell lung cancer.
At the 2023 ACRO Radiation Oncology Summit, Maria Werner-Wasik, MD, discussed preoperative treatment options for stage III non-small cell lung cancer.
At the 2023 ACRO Radiation...
03/20/2023
Oncology
Maria Werner-Wasik, MD, Sidney Kimmel Cancer Center
Videos
How Preoperative Chemoimmunotherapy May Change Management of Patients With Stage III Non-Small Cell Lung Cancer
03/20/2023
At the 2023 ACRO Radiation Oncology Summit, Maria Werner-Wasik, MD, discussed preoperative treatment options for stage III non-small cell lung cancer.
At the 2023 ACRO Radiation Oncology Summit, Maria Werner-Wasik, MD, discussed preoperative treatment options for stage III non-small cell lung cancer.
At the 2023 ACRO Radiation...
03/20/2023
Oncology
Quiz
Quiz: Does Metoformin, CCRT Combo Improve OS in NSCLC?
03/30/2022
True or false: Results from a randomized clinical trial suggest that adding metformin to concurrent chemoradiation (CCRT) does not improve survival in patients with unresectable stage III non-small cell lung cancer.
True or false: Results from a randomized clinical trial suggest that adding metformin to concurrent chemoradiation (CCRT) does not improve survival in patients with unresectable stage III non-small cell lung cancer.
True or false: Results from a...
03/30/2022
Oncology
Adding Metformin to CCRT Does Not Improve Survival in NSCLC
03/23/2022
Although adding metformin to concurrent chemoradiation was well tolerated, it offered no survival benefit for patients with unresectable stage III NSCLC.
Although adding metformin to concurrent chemoradiation was well tolerated, it offered no survival benefit for patients with unresectable stage III NSCLC.
Although adding metformin to...
03/23/2022
Oncology
Quiz
Quiz: Does Nivolumab Impact Surgical Outcomes in Residual Disease?
03/16/2022
According to data presented at the ACRO conference, adjuvant nivolumab following surgery for patients with residual pathological disease results in a doubling of DFS.
According to data presented at the ACRO conference, adjuvant nivolumab following surgery for patients with residual pathological disease results in a doubling of DFS.
According to data presented at...
03/16/2022
Oncology
elderly screening patient
Quiz
Novel MS-VMAT Technique for Whole Lung Irradiation
03/15/2022
At the 2022 ACRO Annual Meeting, experts revealed that a dosimetric advantage was observed with bone marrow sparing VMAT over the standard technique for whole lung irradiation.
At the 2022 ACRO Annual Meeting, experts revealed that a dosimetric advantage was observed with bone marrow sparing VMAT over the standard technique for whole lung irradiation.
At the 2022 ACRO Annual Meeting,...
03/15/2022
Oncology
Dr Chuong
Videos
Dr Chuong Highlights Ablative MR-Guided Radiation Therapy in Inoperable Pancreatic Cancer
10/04/2021
Michael Chuong, MD, Miami Cancer Institute, discusses a 5 day, minimally invasive, ablative MR-guided radiation therapy, proven to maintain a high quality of life in patients with inoperable pancreas cancer.
Michael Chuong, MD, Miami Cancer Institute, discusses a 5 day, minimally invasive, ablative MR-guided radiation therapy, proven to maintain a high quality of life in patients with inoperable pancreas cancer.
Michael Chuong, MD, Miami Cancer...
10/04/2021
Oncology
Quiz
Quiz: Dose Escalation in Esophageal Cancer
08/15/2021
True or false: According to experts who presented at the ACRO Annual Conference, dose escalation is achievable for patients with esophageal cancer.
True or false: According to experts who presented at the ACRO Annual Conference, dose escalation is achievable for patients with esophageal cancer.
True or false: According to...
08/15/2021
Oncology
CXB After EBRT/EBCRT in Patients With Rectal Cancer Not Eligible for Surgery
Interview
CXB After EBRT/EBCRT in Patients With Rectal Cancer Not Eligible for Surgery
01/28/2020
Arthur Sun Myint, FRCP, FFRCS, FRCR, FICS, discusses the significance of a trial on the role of CXB after EBRT or EBCRT in certain patients with rectal cancer.
Arthur Sun Myint, FRCP, FFRCS, FRCR, FICS, discusses the significance of a trial on the role of CXB after EBRT or EBCRT in certain patients with rectal cancer.
Arthur Sun Myint, FRCP, FFRCS,...
01/28/2020
Oncology

At the Radiation Oncology Summit: ACRO, attendees can learn about the latest research updates in radiation oncology and network with like-minded colleagues in the radiology space.

What Your Colleagues are Reading

Jeff Sharman, MD
Conference Coverage
Efficacy of Acalabrutinib With or Without Obinutuzumab Among Patients With Treatment-Naive CLL
12/11/2023
At the 65th ASH Annual Meeting, Jeff Sharman, MD, presented findings from a 6-year follow-up of the ELEVATE-TN trial, which indicated that acalabrutinib with or without obinutuzumab continued to yield promising efficacy outcomes among...
At the 65th ASH Annual Meeting, Jeff Sharman, MD, presented findings from a 6-year follow-up of the ELEVATE-TN trial, which indicated that acalabrutinib with or without obinutuzumab continued to yield promising efficacy outcomes among...
At the 65th ASH Annual Meeting,...
12/11/2023
Oncology
Popular Fecal Immunochemical Tests Equally Effective for Detecting Colorectal Cancer
08/15/2018
Two widely used fecal immunochemical tests show no significant difference in their ability to detect colorectal cancer and advanced neoplasia, according to new findings from the Netherlands.
Two widely used fecal immunochemical tests show no significant difference in their ability to detect colorectal cancer and advanced neoplasia, according to new findings from the Netherlands.
Two widely used fecal...
08/15/2018
Oncology
Claire Harrison, MD, FRCP, Guy’s and St. Thomas’ NHS Foundation Trust
Conference Coverage
Ruxolitinib Therapy Demonstrates Reduced JAK2 Allele Burden and Improvement in Hematocrit Control and Symptom Burden for Patients With PV
12/21/2023
At the 65th ASH Annual Meeting in San Diego, California, Claire Harrison, MD, FRCP discussed a pooled efficacy analysis that provided further evidence of the benefit of ruxolitinib treatment for patients with polycythemia vera, with or...
At the 65th ASH Annual Meeting in San Diego, California, Claire Harrison, MD, FRCP discussed a pooled efficacy analysis that provided further evidence of the benefit of ruxolitinib treatment for patients with polycythemia vera, with or...
At the 65th ASH Annual Meeting...
12/21/2023
Oncology
Second Primary Malignancy Risk Doubled After Head and Neck Cancer
07/26/2018
The risk of second primary malignant neoplasm doubles after a first head and neck squamous cell carcinoma.
The risk of second primary malignant neoplasm doubles after a first head and neck squamous cell carcinoma.
The risk of second primary...
07/26/2018
Oncology
News
Addition of Canakinumab to First-Line Pembrolizumab Plus Chemotherapy Did Not Prolong Survival Outcomes Among Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
01/09/2024
According to results from the CANOPY-1 trial, the addition of canakinumab to first-line pembrolizumab plus chemotherapy did not prolong PFS or OS among patients with advanced or metastatic non-small cell lung cancer who do not harbor ALK or...
According to results from the CANOPY-1 trial, the addition of canakinumab to first-line pembrolizumab plus chemotherapy did not prolong PFS or OS among patients with advanced or metastatic non-small cell lung cancer who do not harbor ALK or...
According to results from the...
01/09/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use